North America Stem Cell Therapy Market Segments, Opportunities, Regional Forecast To 2028

The North America stem cell therapy market was valued at US$ 1,299.39 million in 2022 and is projected to reach US$ 3,582.26 million by 2028; it is expected to grow at a CAGR of 18.4% from 2022 to 2028.

Increasing Research Activities Related to Stem Cell Therapy for Effective Disease Management is Driving the North America Stem Cell Therapy Market

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. The FDA has also approved a few stem cell therapies involved in treating complications related to stem cell transplants. In September 2021, the US Food and Drug Administration (FDA) announced approval for “Ruxolitinib” for treating “graft-versus-host-disease” (GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope that suffers from fatal complications associated with stem cell transplants.

๐Ÿ“š๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐๐ƒ๐… ๐‚๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/BMIRE00028486

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medicals conditions, including immune system diseases, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and cancer types such as leukemia and lymphoma.

๐“๐ก๐ž ๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ

MEDIPOST

RichSource

BioTime, Inc.

Mesoblast Limited

U.S. Stem Cell, Inc.

TiGenix NV

AlloSource

NuVasive Inc

๐Ÿ“š๐…๐ฎ๐ฅ๐ฅ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐‹๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-stem-cell-therapy-market

  • Segments Covered

 

By Type

  • Adult Stem Cell Therapy
  • Embryonic Stem Cell Therapy
  • Induced Pluripotent Stem Cell Therapy
  • Other Stem Cell Therapy

By Treatment

  • Allogeneic
  • Autologous

By Application

  • Musculoskeletal
  • Dermatology
  • Cardiology
  • Drug Discovery & Development
  • Other Applications

By End User

  • Hospitals & Specialty Clinics
  • Academic & Research Institutes

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

stephen johnson
Author: stephen johnson